Phaseline

Companies › Beijing Biostar Pharmaceuticals

Beijing Biostar Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Utidelone Capsule (UTD2)
Microtubule stabilizer; tubulin inhibitor
TubulinPhase 2Gastric or Gastroesophageal Junction Adenocarcinoma; Advanced Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05700084Utidelone Capsule (UTD2)Phase 1Advanced Solid TumorOncologyDec 2026
NCT05700084Utidelone Capsule (UTD2)Phase 1Advanced Solid TumorOncologyDec 2026
NCT06841679Utidelone Capsule (UTD2)Phase 2Gastric or Gastroesophageal Junction AdenocarcinomaOncologySep 2030

Targets

Tubulin (1)

Companies with the same targets

Roche Takeda Sichuan Kelun-Biotech Biopharmaceutical Pfizer AbbVie RemeGen Fidia Farmaceutici GSK Urotronic Ambrx

Companies built like this

Fidia Farmaceutici Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.